EUCTR2018-002850-58-FR进行中（未招募）1 期
A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED QUALITY OF LIFE - EMBRACE
Celgene International II SAR0 个研究点目标入组 255 人开始时间: 2018年12月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 255
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subject is = 18 years of age at the time of signing the informed consent form (ICF).
- •2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
- •3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
- •4. Subject has diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline.
- •5. Subject has a PASI score ranging from =3 to = 10 at baseline.
- •6. Subject has a DLQI score > 10 at baseline.
- •7. Subject has presence of = 1 clinical manifestations of plaque psoriasis, defined as at least one of the following:
- •a. Moderate to severe scalp psoriasis, defined as Scalp Physician Global Assessment (ScPGA) = 3
- •b. Nail psoriasis, defined as onycholysis and onychodystrophy in at least 2 fingernails
- •c. Moderate to severe genital plaque psoriasis, defined as modified static Physicians Global Assessment of Genitalia (sPGA-G) = 3
- •d. Moderate to severe palmoplantar psoriasis, defined as Palmoplantar Psoriasis Physicians Global Assessment (PPPGA) = 3
- •e. Moderate to severe plaque psoriasis in visible locations (dorsal hand, face, neck, and hairline) with static Physicians Global Assessment (sPGA) = 3
- •8. Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories.
- •(NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions.)
- •9. Subject must have failed to respond to, be contraindicated to, or intolerant to other conventional systemic therapy (including, but not limited to, cyclosporine, methotrexate, acitretin, OR fumaric acid esters) or biologic therapies.
- •10. Subjects (in Italy only) must be non-responder to, contraindicated to, or intolerant to other systemic therapy (including cyclosporine, methotrexate, or PUVA) AND also be contraindicated to, or intolerant to biologics.
- •11. Females of childbearing potential (FCBP)† must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive(§) options described below:
- •Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner’s vasectomy;
- •Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
- •A female of childbearing potential is defined as a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had mens
排除标准
- •1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- •2. Subject has any condition, including other inflammatory diseases or dermatologic conditions, which confounds the ability to interpret data from the study, including other types of psoriasis (ie, erythrodermic, or guttate), other than plaque psoriasis, inverse psoriasis.
- •3. Subject has history of drug-induced psoriasis.
- •4. Subject has arthritis that requires systemic treatment.
- •5. Subject unable to avoid use of tanning booths for at least 4 weeks prior to baseline and during study.
- •6. Subject is currently enrolled in any other clinical trial involving an investigational product.
- •7. Other than psoriasis, subject has any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
- •8. Malignancy or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell
- •in situ skin carcinomas.
- •9. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed and the infection cured, at least 4 weeks prior to Screening and no new or recurrent infections prior to the Baseline Visit.
- •10. Subject has received a live vaccine within 3 months of baseline or plans to do so during study.
- •11. Subject is a pregnant or breastfeeding (lactating) woman.
- •12. Subject has used topical therapy within 2 weeks of randomization (including, but not limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, anthralin/dithranol, or moisturizers which contain urea or salicylic acid). Use of phototherapy within 4 weeks prior to randomization. Use of conventional systemic therapy or systemic corticosteroids within 4 weeks prior to randomization, except for conditions other than psoriasis or psoriatic arthritis. Use of biologic therapy within 5 pharmacokinetic half-lives.
- •13. Prior treatment with apremilast, or participation in a clinical study, involving apremilast.
- •14. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
- •15. Subject has any condition that confounds the ability to interpret data from the study.
研究者
相似试验
进行中（未招募）
1 期
Impact of apremilast in patients with specific manifestations of plaque psoriasis and a significantly impaired quality of life.Plaque PsoriasisEUCTR2018-002850-58-GBAmgen Inc.255
进行中（未招募）
1 期
Impact of apremilast in patients with specific manifestations of plaquepsoriasis and a significantly impaired quality of life.Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2018-002850-58-ITCELGENE INTERNATIONAL II SàR255
进行中（未招募）
1 期
Impact of apremilast in patients with specific manifestations of plaque psoriasis and a significantly impaired quality of life.MedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858Plaque PsoriasisEUCTR2018-002850-58-DEAmgen Inc.240
进行中（未招募）
1 期
A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or = 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).EARLY, OLIGOARTICULAR PSORIATIC ARTHRITISMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2018-002735-26-NLCelgene Corporation330
进行中（未招募）
1 期
A clinical study to test the effects of a apremilast compared to placebo for the treatment of patients with Psoriatic Arthritis with less than 2 years of duration and up to 4 joints involved, despite stable treatment with either non-steroidal anti-inflammatory drugs (ie aspirin, ibuprofen and naproxyn) and /or = 1 non-biologic disease-modifying antirheumatic drugs (methotrexate OR sulfasalazine).EARLY, OLIGOARTICULAR PSORIATIC ARTHRITISMedDRA version: 20.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2018-002735-26-FRCelgene Corporation330